Japan Genetic Testing Market Report 2026

Market Size in 2025: USD 651.9 Million

Market Forecast in 2034: USD 4,109.2 Million

Market Growth Rate: 22.70% (2026-2034)

According to the latest report by IMARC Group, titled "Japan Genetic Testing Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034," the Japan genetic testing market size reached USD 651.9 Million in 2025. Looking forward, the market is expected to reach USD 4,109.2 Million by 2034, exhibiting a CAGR of 22.70% during the forecast period from 2026 to 2034.

Download a Free Sample Report: https://www.imarcgroup.com/japan-genetic-testing-market/requestsample

Japan Genetic Testing Market Trends and Demands in 2026

The Japan genetic testing market is experiencing growing demand in 2026 as healthcare providers increasingly use genomic information to support disease detection, risk assessment, diagnosis, and treatment decisions. Advances in sequencing technologies are making genetic analysis more accessible across clinical and research applications, while growing interest in personalized healthcare is encouraging the use of patient-specific genetic information. Genetic testing is being applied across areas including oncology, inherited disorders, reproductive health, and pharmacogenomics. The increasing focus on early disease identification and targeted treatment is also supporting adoption among hospitals, diagnostic laboratories, and specialized healthcare facilities. At the same time, improvements in testing accuracy, turnaround times, data analysis, and laboratory technologies are helping expand the potential applications of genetic testing within Japan’s evolving healthcare system.

Key Japan genetic testing market trends in 2026 include greater adoption of next-generation sequencing, molecular diagnostics, cancer-related genetic testing, and personalized medicine applications. Healthcare professionals are increasingly interested in genomic data that can help identify disease-associated mutations and support more informed treatment strategies. Demand is also developing around screening for inherited conditions and the identification of genetic factors that may influence treatment response. As testing volumes increase, laboratories and healthcare organizations are placing greater emphasis on data management, analytical capabilities, test accuracy, and efficient workflows. Regulatory considerations, privacy, and responsible handling of genetic information remain important factors influencing market development. For diagnostic laboratories, healthcare providers, biotechnology companies, and investors, these trends are creating opportunities across Japan’s genetic testing market.

How AI is Reshaping the Future of the Japan Genetic Testing Market

• Variant Interpretation and Classification: Artificial intelligence analyzes sequencing data to identify and prioritize genetic variants linked to hereditary conditions. Machine learning algorithms compare variants against large genomic datasets to support classification. Predictive systems reduce manual review time and improve the consistency of test reports.
• Risk Prediction and Pharmacogenomic Decision Support: AI-powered systems combine genetic and clinical data to estimate disease risk. Machine learning models predict how patients may respond to specific medications based on their genotype. Predictive systems support personalized treatment selection in cancer, cardiovascular, and neurological care.
• Sequencing Workflow and Quality Control Automation: Artificial intelligence automates sample tracking, data processing, and quality checks across testing laboratories. Machine learning algorithms detect errors and anomalies in sequencing runs. Predictive systems improve turnaround times and support scalable DNA sequencing operations.

Japan Genetic Testing Market Segmentation

The market report offers a comprehensive analysis of the segments, highlighting those with the largest Japan genetic testing market share. It includes forecasts for the period 2026-2034 and historical data from 2020-2025 for the following segments.

Type Insights:

• Predictive and Presymptomatic Testing
• Carrier Testing
• Prenatal and Newborn Testing
• Diagnostic Testing
• Pharmacogenomic Testing
• Others

The report has provided a detailed breakup and analysis of the market based on the type. This includes predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and others.

Technology Insights:

• Cytogenetic Testing and Chromosome Analysis
• Biochemical Testing
• Molecular Testing (DNA Sequencing and Others)

A detailed breakup and analysis of the market based on the technology has also been provided in the report. This includes cytogenetic testing and chromosome analysis, biochemical testing, and molecular testing (DNA sequencing and others).

Application Insights:

• Cancer Diagnosis
• Genetic Disease Diagnosis
• Cardiovascular Disease Diagnosis
• Others

The report has provided a detailed breakup and analysis of the market based on the application. This includes cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others.

Regional Insights:

• Kanto Region
• Kansai/Kinki Region
• Central/Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region

Request a Customized Version of This Report for Deeper Insights: https://www.imarcgroup.com/request?type=report&id=16295&flag=E

Competitive Landscape

Key Players:

• Sysmex Corporation
• SRL, Inc.
• BML, Inc.
• LSI Medience Corporation
• Fujirebio Holdings, Inc.
• A.D.A.M. Innovations Co. (Genesis Healthcare Co.)

Recent News and Developments in Japan Genetic Testing Market

• July 2026: Sysmex announced that its PrismGuide APOE Genotyping Kit received insurance coverage in Japan, effective July 1, 2026. It is the first insured genetic test for assessing the risk of adverse reactions (ARIA) to anti-amyloid β antibody drugs used to treat Alzheimer's disease.
• March 2026: Oxford Nanopore Technologies and A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.) signed a memorandum of understanding at the British Embassy in Tokyo to deploy nanopore sequencing across A.D.A.M. Innovations' genetic testing portfolio.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

Street: 563-13 Kamien
Country: Tokyo, Japan
Postal Code: 4380111
Email: sales@imarcgroup.com

Source: IMARC Group